2024 – Page 7 – Talk Bio

Regeneron’s EYLEA HD Succeeds in Phase 3 Trial for Retinal Vein Occlusion, Paving Way for 2025 FDA Submission

9 months ago talkbio0Tagged aflibercept, dosing, Extension, Eylea, Hodgkin Disease, Interval, Phase 3 QUASAR trial, Regeneron, Retinal Vein Occlusion, Submission, United States Food and Drug Administration

EYLEA HD, Aflibercept, Retinal Vein Occlusion (RVO), Phase 3 QUASAR Trial, Extended Dosing Intervals, FDA Submission 2025, Regeneron Pharmaceuticals

EU Regulator to Investigate Potential Link Between Ozempic and Rare Eye Condition NAION

9 months ago talkbio0Tagged Agencies, Diabetes, European (ethnic group), Evaluation, NAION, Nordisk, Ozempic, semaglutide

Ozempic, NAION, European Medicines Agency, Novo Nordisk, semaglutide, eye disorder, diabetes drug, investigation

Aurion Biotech’s AURN001 Shows Significant Vision Improvement in Phase 1/2 Trial for Corneal Edema

9 months ago talkbio0Tagged allogeneic cell therapy, AURN001, Clinical Trials, Corneal edema, Corneal endothelial dysfunction, Regenerative Medicine

AURN001, corneal edema, corneal endothelial dysfunction, allogeneic cell therapy, regenerative medicine, clinical trial results

Candid Therapeutics Expands T-Cell Engager Pipeline with Strategic Collaborations

9 months ago talkbio0Tagged Autoimmune Diseases, Biotechnology, biotherapeutics, Candid, Collaboration, engagers, Nona Biosciences, T-Lymphocyte

T-cell engagers, autoimmune diseases, biotechnology, Candid Therapeutics, collaborations, EpimAb Biotherapeutics, Nona Biosciences

Roche Discontinues Second Hemophilia A Gene Therapy Candidate Under Spark Amid Shift in Hematologic Portfolio

9 months ago talkbio0Tagged gene therapy, Hemlibra, Hemophilia A, Roche (company)

Roche, Spark Therapeutics, Hemophilia A, Gene Therapy, RG6358, SPK-8016, Hemlibra, SPK-8011

Regeneron and Bayer Achieve Phase III Success with High-Dose Eylea for Retinal Vein Occlusion, Paving Way for Label Expansion

9 months ago talkbio0Tagged Bayer, Biosimilars, competition, expansion, Eylea HD, Macular retinal edema, Phase 3 Clinical Trials, Regeneron, Retinal Vein Occlusion

Regeneron, Bayer, Eylea HD, Retinal Vein Occlusion (RVO), Macular Edema, Phase III Trial, Label Expansion, Biosimilar Competition

Sandoz Reaches $275 Million Settlement in US Generic Drug Price Fixing Case

9 months ago talkbio0Tagged Antitrust, Drug Industry, drug price fixing, Litigation, sandoz, settlement

Sandoz, generic drug price fixing, settlement, antitrust litigation, pharmaceutical industry

Terray Therapeutics and Gilead Sciences Collaborate on AI-Driven Drug Discovery to Accelerate Small Molecule Therapies

9 months ago talkbio0Tagged Drug Discovery, experimentation, Generative AI, Gilead Sciences, high-throughput, small molecule therapies, strategic collaboration, Terray Therapeutics, tNova

AI-driven drug discovery, Terray Therapeutics, Gilead Sciences, Small molecule therapies, tNova platform, High-throughput experimentation, Generative AI, Strategic collaboration

Jazz Pharmaceuticals Announces CEO Succession Plan as Co-Founder Bruce Cozadd Prepares to Retire

9 months ago talkbio0Tagged biopharmaceutical company, BIRC6 gene, CEO, Cozadd, Jazz, Leadership, Retirement, Succession Plan

Jazz Pharmaceuticals, Bruce Cozadd, CEO succession plan, retirement, biopharmaceutical company, leadership transition

Congress Eyes Major PBM Reforms in Year-End Spending Bill

9 months ago talkbio0Tagged Benefit Managers, bipartisan, Congress, Congress (U.S. Legislature), Health care facility, Legislation, PBMs, Pharmaceutical Services, Pharmacy Benefit Manager, Prices, reforms, spending, Translucent, year-end

Pharmacy Benefit Managers (PBMs), PBM reforms, healthcare costs, year-end spending bill, Congress, bipartisan legislation, transparency, drug prices.